GlycoMimetics fails phase 3 blood cancer trial, sinking stock fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population
Adverse events were consistent with known side effect.
Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.
Operator: Good morning, and thank you for joining the GlycoMimetics Q4 and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.